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Abstract
Background: We previously demonstrated that the plant-derived agent a-bisabolol enters cells via lipid rafts, binds
to the pro-apoptotic Bcl-2 family protein BID, and may induce apoptosis. Here we studied the activity of a-
bisabolol in acute leukemia cells.
Methods: We tested ex vivo blasts from 42 acute leukemias (14 Philadelphia-negative and 14 Philadelphia-positive
B acute lymphoid leukemias, Ph-/Ph+B-ALL; 14 acute myeloid leukemias, AML) for their sensitivity to a-bisabolol in
24-hour dose-response assays. Concentrations and time were chosen based on CD34+, CD33+my and normal
peripheral blood cell sensitivity to increasing a-bisabolol concentrations for up to 120 hours.
Results: A clustering analysis of the sensitivity over 24 hours identified three clusters. Cluster 1 (14 ± 5 μM a-
bisabolol IC50) included mainly Ph
-B-ALL cells. AML cells were split into cluster 2 and 3 (45 ± 7 and 65 ± 5 μM
IC50). Ph
+B-ALL cells were scattered, but mainly grouped into cluster 2. All leukemias, including 3 imatinib-resistant
cases, were eventually responsive, but a subset of B-ALL cells was fairly sensitive to low a-bisabolol concentrations.
a-bisabolol acted as a pro-apoptotic agent via a direct damage to mitochondrial integrity, which was responsible
for the decrease in NADH-supported state 3 respiration and the disruption of the mitochondrial membrane
potential.
Conclusion: Our study provides the first evidence that a-bisabolol is a pro-apoptotic agent for primary human
acute leukemia cells.
Background
a-bisabolol is a small oily sesquiterpene alcohol (Figure
1A) that has been demonstrated to have activity against
some malignant adherent human and rat cell lines [1]
and against spontaneous mammary tumors in HER-2
transgenic mice [2]. We have previously found that it
enters cells via lipid-rafts, interacts directly with BID, a
pro-apoptotic BH3-only Bcl-2 family protein, and
induces apoptosis [3].
Here we test the pro-apoptotic potential of a-bisabolol
against primary acute leukemia cells, including Philadel-
phia-negative and -positive B acute lymphoid leukemias
(Ph-/Ph+B-ALL) and acute myeloid leukemias (AML),
and against normal blood white cells and hematopoietic
bone marrow stem cells. Leukemic blasts represent a
unique model to study the activity of a-bisabolol due to
their biology allowing easy manipulation and evaluation.
Moreover, acute leukemia treatment in adults is unsatis-
factory despite investigations over the past four decades
of a wide variety of anti-leukemic agents, refinement of
bone marrow transplantation and the development of
specific targeted therapy [4,5]. There is a particular need
for treatments with both high efficacy and low toxicity
[6] based on new molecules with mechanisms of action
different from conventional drugs. This is especially true
for elderly leukemia patients, who represent the majority
of cases and have fewer therapeutic options [7]. Like-
wise, despite the introduction of anti-BCR/ABL tyrosine
kinases for the treatment of Ph+ leukemias, it seems
that identification of novel compounds is perhaps neces-
sary for success in eradicating Ph+ cells [8,9].
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The present study shows that a-bisabolol enters acute
leukemic cells, where it disrupts the mitochondrial
membrane potential and triggers apoptosis. Interestingly,
a-bisabolol seems to be a much more effective agent in
some Ph-B-ALL cells than in other types of acute leuke-
mias at dosages that spare normal leukocytes and hema-
topoietic stem cells.
Methods
Patients and ethical requirements
Blasts from 28 patients with B-lineage ALL (14 Ph-, 14
Ph+B-ALL) and 14 with AML diagnosed at our institu-
tion, as well as blood and bone marrow cells from five
healthy control donors, were collected after written
informed consent was obtained, according to Italian law.
All cellular studies were approved by the Verona Uni-
versity Hospital ethics committee. Patient characteristics
are detailed in Table 1. The diagnosis of B-ALL or AML
and their subtypes was based on clinical findings and on
established morphological, cytochemical, cytofluori-
metric, cytogenetic and molecular features of peripheral
blood and bone marrow cells. AML patients received
three induction courses according to standard AML
treatment (1st course: 3-day idarubicin + 7-day AraC by
continuous i.v. infusion; 2nd course: 3-day idarubicin +
3-day high-dose AraC; 3rd course: 3-day high-dose
AraC). B-ALL patients were treated with induction and
maintenance therapy according to the VR95ALL proto-
col [10], which has been subsequently developed into
the GIMEMA 0496 ALL protocol [11]. Young B-ALL
patients (<18 years) were treated according to a specific
pediatric protocol [12]. Ph+B-ALL patients underwent
differential treatment including BCR/ABL TKI. Allo-
geneic bone marrow transplantation was performed dur-
ing the first complete remission in four Ph-B-ALL cases
and four Ph+B-ALL cases.
Cells
1. Primary Leukemic cells
Viable leukemic cells were purified by conventional
methods from freshly heparinized peripheral blood with a
circulating blast count ≥30,000/mL, or from full-substi-
tuted bone marrow that was frozen in liquid nitrogen at
diagnosis [13]. In all cases frozen cell samples contained
>95% blasts. Cell viability after thawing was always >90%,
as assessed by trypan blue staining.
2. Normal cells
Viable peripheral blood leukocytes [14] and bone marrow
cells from - 4 - control donors were treated and used as
specified above for leukemic cells.
3. Cell line
The imatinib-sensitive BCR/ABL+ CML-T1 cell line
(T-lineage blast crisis of human chronic myeloid leuke-
mia, purchased from DSMZ, Braunschweig, DE) was
used to perform synergism studies.
Measurement of a-bisabolol concentrations in the
culture medium
a-bisabolol at a purity ≥95% (GC) was purchased from
Sigma-Aldrich, St. Louis, MO. The dose-dependent solu-
bilization of a-bisabolol in the culture medium over 24
hours was determined by a reverse-phase high perfor-
mance liquid chromatography (RP-HPLC) method, devel-
oped in the Department of Food Science of Bologna
University, Cesena office, Italy. All measurements were
performed in duplicate. The a-bisabolol concentrations
indicated throughout the article represent the calculated
soluble fraction in the assay.
Cytotoxicity assays
Cells derived from patients or normal donors were
exposed for 24 hours to 20, 40, 80, and 160 μM a-bisa-
bolol dissolved in ethanol (1:8 in order to minimize
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Figure 1 a-bisabolol structure and solubilization in the culture
medium. (A) a-bisabolol is a small oily sesquiterpene alcohol with a
molecular mass of 222.37 Da. (B) 250 μM a-bisabolol was added to
culture medium: concentration raised during the first 3 hours, then
lowered to around 65% of the initially added a-bisabolol after 24
hours. (C) By this time, the linear function relating added to
measured concentrations of a-bisabolol shows that the incremental
ratio was 0.65 for 14 evaluations representing a double series of 7
scaled concentrations tested by a RP-HPLC method. Each point is
the mean ± SD of 2 measurements.
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Table 1 Patients’ characteristics.
patient sex age diagnosis Karyotype
mol biol
therapy* response§ relapse OS§§
Ph- B-ALL
#01 M 22 B common normal 1 + 2 CR Yes 29+
#02 M 40 Pre-B NA 1 + 2 CR No 24+
#03 M 16 B common normal 1 CR Yes 12
#04 M 45 Pre-B normal 1 + 2 CR No 38+
#05 F 53 B common hyperdiploid 1 CR No 71+
#06 F 48 Pro-B t(4;11) 1 CR Yes 8
#07 F 42 Pro-B t(4;11) 1 CR Yes 6
#08 M 41 Pre-B t(6;8) 1 CR Yes 19
#09 M 59 Pro-B t(4;11) 1 CR Yes 10
#10 F 19 B common hyperdiploid 1 CR No 55+
#11 M 17 B common t(17;22) 3 CR No 9+
#12 F 53 B common NA 1 CR Yes 13+
#13 F 43 B common normal 1 + 2 CR Yes 25
#14 F 17 B common normal 3 NR Yes 4
Ph+ B-ALL
#01 M 44 Pre-B Ph masked
p210 (Y253H)
IM + D + 2 CR No 12+
#02 F 54 B common t(9;22)
p210
1 (pre-IM) no CR 36
#03 M 64 Pre-B t(9;22)
p210
IM CHR, CCyR Yes 9
#04 M 19 B common t(9;22)
NA (E255V)
1 + IM + N no CHR 16
#05 M 40 Pre-B t(9;22),-10
p210
1 + IM + D CHR, CCyR Yes 15
#06 F 38 Pre-B t(9;22)
p190 (T315I)
1 + IM + D no CHR 9
#07 M 17 B common t(9;22)
p210
1 (pre-IM) + 2 CR Yes 11
#08 M 70 Pre-B t(9;22)
NA
5 (pre-IM) no CR 1
#09 M 35 B common t(9;22), del(6)
p190
1 + IM + 2 CCyR, MMR No 46+
#10 M 63 B common t(9;22)
p190
IM + CS CCyR, MMR No 15+
#11 F 75 B common hyperdiploid, t(9;22), NA 5 (pre-IM) no CR 14
#12 M 89 Pre-B t(9;22)
p190
IM CCyR, MMR Yes 22+
#13 F 27 B common t(9;22)
p190
1 + IM no CHR 10
#14 M 28 B common t(9;22)
p190
1 + IM + 2 CR Yes 37
AML
#01 M 59 M2 +4,+8 4 PR Yes 7
#02 M 46 M0 NA 4 TD 1
#03 F 37 M4 del(X)(p21) 4 CR No 167+
#04 F 47 M2 normal 4 NR Yes 20
#05 F 70 M4 Eo inv(16) 4 NR no CR 6
#06 M 74 M4 normal 5 2
#07 M 62 M4 normal 4 NR no CR 5
#08 M 69 M4 Eo NA 5 5
#09 M 60 M2 -7 4 CR No 38+
#10 M 83 M2 NA 5 3
Cavalieri et al. Journal of Translational Medicine 2011, 9:45
http://www.translational-medicine.com/content/9/1/45
Page 3 of 13
drug volumes), and when appropriate to 3 μM imatinib
mesylate (Novartis, Basel, CH), representative of the in
vivo active concentration. All cytotoxicity tests were per-
formed in triplicate.
1. Homogeneous cell populations
A lactate dehydrogenase (LDH) release assay was con-
ducted as follows. Thawed cells were resuspended in
RPMI-1640 (Lonza, Basel, CH) supplemented with 10%
heat-inactivated fetal bovine serum (FBS, Lonza), 50 U/mL
penicillin and 50 μg/mL streptomycin (complete medium,
CM), seeded at a density of 2 × 106 cell/mL and incubated
at 37°C in 5% CO2. After 24 hours, the cells were treated
with a-bisabolol (or ethanol as a vehicle control) as speci-
fied above. Cytotoxicity was determined using the Cyto-
toxicity Detection KitPLUS according to the manufacturer’s
recommendations (Roche, Mannheim, DE). LDH leakage
was measured as the ratio of treatment-induced LDH to
spontaneous LDH release. a-bisabolol and imatinib mesy-
late data were reported as the percent cytotoxicity for
treated compared to untreated cells and plotted as
dose-response curves over 24 hours. The half maximal
inhibitory concentration (IC50) was determined when
appropriate.
2. Heterogeneous cell populations
The absolute counts of normal leukocytes sub-popula-
tions were measured with TruCOUNT tubes (Becton
Dickinson, San Jose, CA) by polychromatic flow cytome-
try according to the manufacturer’s instructions with
minor modifications. Peripheral blood and bone marrow
cells were cultured with a-bisabolol for 24, 48, 72, 96
and 120 hours. At the end of the culture, 200 μL of sam-
ple, a mixture of antibodies (CD45 APC-H7, CD3 PE-
Cy7, CD19 PE, CD14 APC for peripheral blood and
CD45 APC-H7, CD34 PE, CD33 PE-Cy7 for bone mar-
row) and 7-amino-actinomycin D (all reagents from Bec-
ton Dickinson) for dead cells exclusion were added to the
TruCOUNT tubes. After a 15-minute incubation at room
temperature, 1 mL lysing reagent (Biosource, Nivelles,
BE) was added for 10 minutes. A total of 40,000 beads
were acquired on a FACSCanto cytometer (Becton Dick-
inson). A sequential Boolean gating strategy was used to
accurately enumerate different populations [15].
Cytotoxicity data hierarchical clustering analysis
To generate a classification based on a-bisabolol sensitiv-
ity, samples were grouped using the complete linkage
hierarchical clustering algorithm available in the MultiEx-
periment Viewer (MeV, version 4.3 - http://www.tm4.
org/mev/). A heat map for sensitivity was derived using
the percentage data for mortality after adding a-bisabolol
with respect to spontaneous mortality at the same time.
Synergism studies
The interactions between imatinib mesylate and a-bisa-
bolol were analyzed according to the median-effect
method of Chou and Talalay [16] using the CalcuSyn
Software (Biosoft, Cambridge, UK). The mean combina-
tion index (CI) values, based on constant drug ratios,
were assessed with the following interpretation: CI>1,
antagonistic effect; CI = 1, additive effect; CI<1, syner-
gistic effect. Combination data were depicted as CI vs.
fraction affected (Fa) plots, defining the CI variability by
the sequential deletion analysis method. The cytotoxicity
was evaluated as described above.
Western blot analysis
Cells were homogenized at 4°C in 50 mM Tris-HCl
(pH 8) containing 0.1% Nonidet-P40 (NP-40), 200 mM
KCl, 2 mM MgCl2, 50 μM ZnCl2, 2 mM DTT, and pro-
tease inhibitors [1 mM phenylmethylsulfonyl fluoride
(PMSF), 1 mg/mL leupeptin, and 1 mg/mL antipain].
Aliquots of the homogenates (40 μg total protein/lane)
were loaded on SDS-polyacrylamide gels at the appro-
priate concentrations. Electrophoresis was performed at
100 V with a running buffer containing 0.25 M Tris-
HCl (pH 8.3), 1.92 M glycine, and 1% SDS. The resolved
proteins were electroblotted onto a nitrocellulose mem-
brane using the iBlot™ system (Invitrogen, Carlsbad,
CA). Membranes were then incubated with a mouse
monoclonal IgG antibody to poly(ADP-ribose) polymer-
ase (PARP) (Zymed, South San Francisco, CA), with a
rabbit polyclonal IgG antibody to BID (Cell Signaling
Technology, Danvers, MA) or with a rabbit polyclonal
IgG antibody to a-tubulin (Cell Signaling Technology).
The membranes were then washed and incubated with
Table 1 Patients’ characteristics. (Continued)
#11 M 88 M2 NA 5 1
#12 F 79 M0 normal 5 9
#13 M 52 M4 normal 4 CR No 24+
#14 F 61 M2 t(11;22) 4 CR Yes 11
*Therapy: 1 = ALLVR589 protocol [10] or subsequent GIMEMA protocol LAL0496 [11]; 2 = allogeneic bone marrow transplantation; 3 = AIEOP-BFM-ALL 2000
protocol [12]; 4 = AML standard treatment (see Matherials and Methods); 5 = supportive care (hydroxicarbamide, blood transfusions etc); CS = corticosteroid;
IM = imatinib; D = dasatinib; N = nilotinib
§NA = not avalaible; CR = complete remission; PR = partial remission; NR = non-responder; TD = toxic death; CHR = complete hematologic remission; CCyR =
complete cytogenetic remission; MMR = major molecular remission (>3 log reduction bcr/abl ratio)
§§+ = ongoing follow-up
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an anti-mouse or anti-rabbit IgG peroxidase-conjugated
antibody (Cell Signaling Technology). The blots were
washed again and then incubated with enhanced chemi-
luminescent detection reagents (Immun-Star™ Wes-
ternC™ Kit, Bio-Rad, Hercules, CA) according to the
manufacturer’s instructions. Proteins were detected
using the ChemiDoc XRS Imaging System (Bio-Rad).
Cytosolic and mitochondrial fraction preparation
Cell pellets were suspended in 100 μL of solution con-
taining 10 mM NaCl, 1.5 mM MgCl2, 10 mM Tris-HCl,
pH 7.5, 1 mM sodium orthovanadate, and complete
EDTA-free protease inhibitor cocktail (Boehringer, Man-
nheim, DE). Cells were then chilled on ice for 10 minutes
and gently lysed by adding 0.3% (v/v) NP-40. In order to
restore an isotonic environment, a solution containing
525 mM mannitol, 175 mM sucrose, 12.5 mM Tris-HCl,
pH 7.5, 2.5 mM EDTA, and protease inhibitor cocktail
was added. Lysates were first centrifuged at 600 × g at 4°
C in order to remove nuclei and then the supernatants
were centrifugated at 17,000 × g for 30 minutes at 4°C.
The obtained supernatants were collected and used as
the cytosolic fraction. The pellets, that contained mito-
chondria, were washed once with the same buffer and
then were resuspended in sample buffer. The cytosolic
and the mitochondrial fractions were separated on a 15%
SDS-PAGE and probed using a rabbit polyclonal IgG
antibody to BID (Cell Signaling Technology). Then, the
membrane with the cytosolic and mitochondrial fractions
were probed with a rabbit polyclonal IgG antibody to a-
tubulin (Cell Signaling Technology) and with a mouse
monoclonal IgG antibody to Hsp60 (Abcam, Cambridge,
UK), respectively.
Cell permeabilization
Leukemic cells and normal lymphocytes were centrifuged
(10 minutes, 200 × g) and washed with ice cold buffer A
(250 mM sucrose, 20 mM HEPES, 10 mM MgCl2 - pH
7.1). The pellet was resuspended in 2 mL of buffer A con-
taining 80 μg of digitonin. After a 1-minute incubation on
ice, 8 mL of buffer A were added and cells were centri-
fuged (3 minutes, 400 × g). The pellet was resuspended in
100 μL buffer A containing 1 mM ADP, 2 mM KH2PO3
(respiration buffer) and immediately used for the polaro-
graphic assay. Cell number and permeabilization was mea-
sured by the trypan blue exclusion method.
Oxygen consumption
Permeabilized leukemic cells and lymphocytes were
assayed for oxygen consumption at 30°C using a thermo-
statically controlled oxygraph and Clark electrode. Cells
were incubated for 10 minutes in respiration buffer at 30°
C in the presence or absence of 3 μM a-bisabolol. Mito-
chondrial respiration (state 3 respiration) was started by
adding 5 mM glutamate plus malate (G/M) and 5 mM
succinate plus glycerol-3-phosphate (S/G3P), which are
complex I and complex III/glycerol-3-phosphate dehydro-
genase substrates, respectively. The maximal respiration
rate (uncoupled respiration) was empirically determined
by the addition of 200 nM carbonylcyanide-4- (trifluoro-
methoxy)-phenylhydrazone (FCCP). Oxygen consumption
was completely inhibited by adding 4 μM antimycin A at
the end of the experiments [17].
Mitochondrial membrane potential evaluation
Cells resuspended in CM at 1 × 106/mL were treated
with 40 μM a-bisabolol for 3 or 5 hours at 37°C. They
were then washed with pre-warmed CM, 4 μM of the
potential sensitive dye JC-1 (5,5’,6,6’-tetra-chloro-
1,1’,3,3’-tetra-ethyl-benz-imidazolyl-carbocyanine iodide,
Molecular Probes, Eugene, OR) was added, and they
were then placed back into the incubator. After 30 min-
utes they were washed twice with pre-warmed PBS. An
aliquot of each sample was spotted onto a slide,
mounted with a coverslip and immediately recorded by
an Axio Observer inverted microscope (Zeiss, Gottingen,
DE). Visualization of JC-1 monomers (green fluores-
cence) and JC-1 aggregates (red fluorescence) was done
using filter sets for fluorescein and rhodamine dyes
(emission 488 and 550 nm respectively). Image captures
of random fields using fixed imaging parameters were
performed, and previously unviewed areas of cells were
captured to avoid photobleaching [18]. Image analysis
was done using Axiovision 3 software. The other aliquot
of each sample was resuspended in PBS and analyzed
using a FACSCalibur cytometer (Becton Dickinson)
equipped with a 488 nm argon laser. The emission of
JC-1 monomers was detected in Fl-1 using a 530/30 nm
bandpass filter, and JC-1 aggregates were detected in Fl-
2 using a 585/42 nm bandpass filter. FlowJo 8.8.2 soft-
ware (Tree Star, Ashland, OR) was used to analyze data
[19].
DNA ladder
For internucleosomal DNA laddering analysis, 5 × 106
cells were resuspended in 0.3 mL of culture medium
containing 10% FBS and incubated for 90 minutes at 65°
C and then overnight at 37°C in the presence of 0.4 M
NaCl, 5 mM Tris-HCl (pH 8), 2 mM EDTA, 4% SDS
and 2 mg/mL proteinase K. The lysates were brought to
a final concentration of 1.58 M NaCl and centrifuged
twice for 10 minutes at 6,000 × g to separate the DNA
fragments from intact DNA. The supernatants were
recovered, and DNA was precipitated by the addition of
three volumes of absolute ethanol at -80°C for 1 hour.
The DNA pellets were recovered by microcentrifugation
(10 minutes, 12,000 × g) and resuspended in a minimal
volume of 40 μl of 10 mM Tris-HCl (pH 7.4), 1 mM
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EDTA, and 1 mg/mL DNase-free ribonuclease A. Ali-
quots of 5 μg of DNA were then loaded onto a 1% agar-
ose gel containing 0.25 μg/mL ethidium bromide. After
electrophoresis, the DNA was visualized by UV light
using the ChemiDoc XRS Imaging System (Bio-Rad).
Statistics
Student’s t-test for means, chi-squared tests, Mann-
Whitney U test and Kruskall-Wallis analysis of variance
by ranks were considered significant for p values < 0.05.
The 24-hour IC50 was approximated by using mean
cytotoxicity data in the different groups (according to
diagnosis or clustering-based analysis).
Results
a-bisabolol concentrations in the culture medium
Due to the lipophilic properties of a-bisabolol, a preli-
minary evaluation was performed of the dose-dependent
solubilization in the culture medium over 24 hours by a
RP-HPLC method. The addition of a-bisabolol at time 0
was followed by a rapid increase of the measured con-
centrations during the first 3 hours. After 24 hours, con-
centrations may be considered roughly constant, though
with a slightly downward trend (Figure 1B). A double
series of 7 determinations corresponding to 0, 3, 15, 30,
60, 125, 250 μM a-bisabolol added to medium gave a
linear function with a 0.65 incremental ratio (Figure
1C), indicating that, after 24 hours, around 65% of the
a-bisabolol added was actually measured in the culture
medium.
a-bisabolol cytotoxicity in normal peripheral blood cells
The viability of normal blood cells was evaluated after
different times and doses of exposure to a-bisabolol.
The cytotoxicity increased in a dose- and time-depen-
dent manner. Figure 2A depicts the sensitivity to
increasing doses of a-bisabolol for up to 120 hours in
each different blood cell subpopulation. T lymphocytes,
which were far less sensitive to a−bisabolol than B-lym-
phocytes, monocytes and neutrophils, had a 24-hour
IC50 of 59 ± 7 μM and were only marginally sensitive to
40 μM a-bisabolol over 120 hours.
a-bisabolol cytotoxicity in normal counterparts of acute
leukemia cells
Figure 2B depicts the sensitivity to a-bisabolol in CD33
+my and CD34+/33+ or CD34+/19+ cells from 5 normal
bone marrow samples. These subpopulations were
assumed to represent the normal counterpart of acute
leukemia blasts and the hematopoietic compartment
that is responsible for bone marrow renewal and, even-
tually, drug toxicity. The 24-hour a-bisabolol IC50 was
95 ± 7 and 62 ± 9 μM in CD33+my and CD34+ cells,
respectively (p < 0.05). By contrast, no difference was
observed between CD34+/33+ and CD34+/19+ cells
(64 ± 6 and 63 ± 4 μM IC50, respectively).
a-bisabolol cytotoxicity in primary acute leukemia cells
by diagnosis
Based on these data from normal cells, we performed ex
vivo dose-response (20, 40 80, and 160 μM a-bisabolol)
cytotoxicity assays at 24 hours in 42 different samples of
leukemic cells (14 Ph-B-ALL, 14 Ph+B-ALL, 14 AML)
obtained from patients before any treatment. Table 1
summarizes the main patients’ characteristics. Table 2
shows the results of the cytoxicity assays as mean ± SD
after 24 hours of exposure to different concentrations of
a-bisabolol, and Figure 3A depicts the corresponding
dose-response curves for Ph-B-ALL, Ph+B-ALL, and
AML cells. The 24-hour dose-response assays showed
that a-bisabolol was cytotoxic to primary Ph-B-ALL cells
(33 ± 15 μM IC50). Though less sensitive, Ph
+B-ALL,
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Figure 2 Cytotoxicity of a-bisabolol in normal hematologic
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the 120-hour cytotoxicity assays. Means ± SD of 5 normal donors
are depicted.
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including Ph+-cells resistant to imatinib mesylate, and
AML cells were also killed (46 ± 11 and 54 ± 8 μM IC50,
respectively; p < 0.05 compared to Ph-ALL). Thus, a-
bisabolol is a pro-apoptotic agent for acute leukemia cells
ex vivo, particularly for Ph-B-ALL.
a-bisabolol cytotoxicity on primary leukemic cells by
clustering analysis
We generated a cytotoxicity-based classification of our
leukemic samples using the complete linkage hierarchi-
cal clustering algorithm available in MultiExperiment
Viewer. As shown in Figure 3B, clustering analysis iden-
tified three main groups (p < 0.05) by comparing differ-
ences among experimental samples with regard to
responsiveness to apoptotic signals induced by a-bisabo-
lol. The group with the highest sensitivity to a-bisabolol
(cluster 1: 14 ± 5 μM IC50) included 2 Ph
+ and 6 Ph-
B-ALL cases. Thus, a proportion of the Ph-B-ALL cases
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Figure 3 24-hourcytotoxicity of a-bisabolol in primary blasts from 42 acute leukemias. (A) a-bisabolol activity against blasts ex vivo, here
grouped by diagnosis. The corresponding IC50 values and number of cases (n) are shown. The differences between the Ph
-B-ALL sensitivity
curves and the other ones were statistically significant (p < 0.05). Each point is the mean ± SD of 14 cases. (B) a-bisabolol sensitivity clustering
analysis. The samples were grouped by complete linkage hierarchical clustering algorithm available in MultiExperiment Viewer http://www.tm4.
org/mev/. The heat map was obtained by subtracting spontaneous mortality to scaled a-bisabolol 24-hour cytotoxicity expressed as percentage.
Three main groups of patients were identified based on their cytotoxicity response. The Ph-B-ALL (ALL) cases shared the highest sensitivity and
were grouped mainly in the first sensitivity cluster, whereas AML cases were split into two groups with intermediate and lower sensitivities. Ph
+B-ALL (Ph+) cells were scattered among the three groups, although they were mainly clustered in the second group. At the bottom, the 24-
hour dose-response curves of the three sensitivity clusters are depicted, and the corresponding IC50 values and number of cases (n) are shown.
The differences between the curves were statistically significant (p < 0.05).
Table 2 a-bisabolol cytotoxicity in acute leukemia cells
and in their normal counterparts (% mean values ± SD
according to a-bisabolol concentration).
μM a-bisabolol 20 40 80 160 IC50 p
Ph-B-ALL 14 37 ± 36 55 ± 37 87 ± 12 100 33 ± 15 <0.05
ns
Ph+B-ALL 14 2 ± 19 42 ± 28 81 ± 17 98 ± 2 46 ± 11
AML 14 10 ± 9 32 ± 21 72 ± 11 96 ± 4 54 ± 8
cluster 1 8 72 ± 24 94 ± 6 99 ± 1 100 14 ± 5 <0.05
<0.05
cluster 2 19 17 ± 9 44 ± 14 77 ± 15 97 ± 3 45 ± 7
cluster 3 15* 3 ± 3 14 ± 8 73 ± 14 98 ± 2 65 ± 5
17§ 2 ± 3 14 ± 8 71 ± 16 97 ± 3 64 ± 5
CD34+ 5 1 ± 2 22 ± 19 72 ± 35 98 ± 1 62 ± 9 ns
<0.05
CD33+my 5 2 ± 2 4 ± 3 40 ± 39 99 ± 1 95 ± 7
*acute leukemia samples.
§15 acute leukemias plus CD34+ and CD33+my samples.
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shared a high sensitivity to a-bisabolol, although some
other Ph-B-ALL were scattered over different sensitivity
groups. The AML cases were split into two groups with
intermediate (cluster 2: 45 ± 7 μM IC50; 7 AML cases)
and lower (cluster 3: 65 ± 5 μM IC50; 7 AML cases) sen-
sitivity. Unlike Ph-B-ALL, AML cases as a whole were
less sensitive to a-bisabolol. The Ph+B-ALL cases were
scattered all over the three groups but were mainly clus-
tered with intermediate sensitivity AML. Interestingly,
introducing both CD34+ and CD33+my cell sensitivity to
a-bisabolol (as the mean value of 5 cases) in clustering
analysis made it evident that ALL cells as a whole were
more sensitive to a-bisabolol than their normal counter-
part (grouped into cluster 3 among less sensitive cells).
This analysis demonstrated that some Ph-B-ALL cases
may be highly sensitive to the apoptotic mechanisms
activated by a-bisabolol and indicated that the Ph+B-
ALL cases and especially the AML cases (these latter
showing a bimodal sensitivity) may well be characterized
by variable degrees of resistance to these mechanisms.
Still, all leukemia cases were eventually responsive to 65
μM a-bisabolol for 24 hours (Table 2). In Figure 4, the
dose-response assays for each case are depicted.
a-bisabolol plus imatinib mesylate in cells bearing
mutated or non-mutated BCR/ABL
a-bisabolol was active against Ph+B-ALL cells (24-hour
IC50 was 46 ± 11 μM; Figure 3). We wondered if a-bisabo-
lol and imatinib mesylate had synergistic effects. As shown
in Figure 5A cells from case Ph+B-ALL #04 (carrying the
E255V mutation, Table 1) were primarily resistant to ima-
tinib mesylate and showed similar ex vivo cytotoxicity
when treated with either a-bisabolol (20, 40 80, and 160
μM for 24 hours) alone or a-bisabolol associated with ima-
tinib mesylate (3 μM for 24 hours representative of in vivo
effective concentration). In contrast, cells sensitive to
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imatinib mesylate shared a significant increase in cytotoxi-
city to a-bisabolol. For instance, cells from patient Ph+B-
ALL #05 (Table 1) shifted from 40% cytotoxicity with
40 μM a-bisabolol alone to 75% with a-bisabolol plus ima-
tinib mesylate. This may suggest that the presence of BCR/
ABL tyrosine kinase activity in a cell reduces the effective-
ness of a-bisabolol as a pro-apoptotic agent or that imati-
nib mesylate reduces the IC50 of a-bisabolol. The imatinib
mesylate-sensitive BCR/ABL+ CML-T1 cell line, a T-cell
lineage blast crisis of CML, was used in order to conclu-
sively calculate the synergism, if any, between imatinib
mesylate and a-bisabolol. Figure 5B shows that the combi-
nation of imatinib mesylate and a-bisabolol resulted in a
higher degree of inhibition of cellular proliferation com-
pared with each inhibitor alone (p < 0.05), and the combi-
nation was clearly synergistic, denoted by CI values <1 for
any given Fa [16]. Also, the combination resulted in a
higher degree of induction of apoptosis (data not shown).
a-bisabolol and BID
We have previously demonstrated that a-bisabolol binds
to the BCL-2 family member BID [3]. To evaluate the
possibility that the treatment with a-bisabolol leads to
the cleavage of BID to truncated BID, we analyzed
whole extract of leukemic cells and normal PBMCs by
Western blot. As shown in Figure 6A, whereas trun-
cated BID is detectable in the human T-cell lympho-
blast-like cell line Jurkat used as a positive control, it is
not present in PBMCs and blasts, indicating that the
pro-apoptotic action of a-bisabolol is not dependent on
BID cleavage. However, caspase cleavage is not an abso-
lute requirement for activating BID pro-apoptotic func-
tion. Full-length BID is also capable of translocation to
the mitochondria, where it has been shown to potentiate
cell death following certain apoptotic signals [20]. But
we were unable to demonstrate full-length BID in the
mitochondria by separating cytosolic and mitochondrial
fraction following a-bisabolol treatment (Figure 6B).
Decrease of mitochondrial state 3 respiration
In a previous paper, we confirmed the mitochondrial
involvement in a-bisabolol-induced cell death by the
measurement of oxygen consumption by intact cells
[21]. In the current work we used permeabilized leuke-
mic cells from 6 patients (3 Ph-B-ALL, 1 Ph+B-ALL,
2AML) and healthy lymphocytes from 6 donors to
determine whether a-bisabolol treatment affects mito-
chondrial state 3 and uncoupled respiration. Figure 6C
shows that NADH-supported state 3 respiration (G/M)
in a-bisabolol-treated leukemic cells was dramatically
decreased in comparison with untreated leukemic con-
trols (140.0 ± 70.5 vs. 280.7 ± 11.9 pmol O2/minute/10
6
cells; p < 0.05). In contrast, the oxygen consumption
sustained by S/G3P oxidation was not affected by a-
bisabolol treatment, and the mitochondrial respiration
was not stimulated by the addition of FCCP. These data
are in line with a loss of mitochondrial integrity in trea-
ted leukemic samples, which is responsible for the
matrix NADH decrease. This behavior is confirmed by
the observation that the respiration in the presence of
S/G3P was unaffected. Healthy lymphocyte respiration
was not statistically modified by a-bisabolol treatment
in state 3 using G/M and S/G3P as substrates and
FCCP as a mitochondrial uncoupler. This is in agree-
ment with the resistance to a-bisabolol observed in
lymphocytes (Figure 2A).
Loss of mitochondrial potential
JC-1 staining [19,22] demonstrated that a-bisabolol dis-
sipates the mitochondrial transmembrane potential
(ΔΨm). In fit cells, JC-1 is more concentrated in the
mitochondria (driven there by the ΔΨm), where it forms
red-emitting aggregates, than in the cytosol, where it
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exists as a green-fluorescent monomer. Accordingly, the
ratio red/green JC-1 fluorescence can be used as a sensi-
tive measure of ΔΨm [23]. Disruption of ΔΨm (a hall-
mark of cytochrome c translocation and the start of the
apoptotic process) is indicated by a loss of red fluores-
cence and an increase in green fluorescence. Figure 7A
shows the representative case Ph-B-ALL #01 out of the
6 tested. Microscopy revealed that in untreated leukemic
cells well-polarized mitochondria were marked by punc-
tate red fluorescent staining (Figure 7A, left side). After
a 3-hour incubation with 40 μM a-bisabolol, this pat-
tern was replaced by diffuse green fluorescence in leuke-
mic cells (Figure 7A, center and right side). Flow
cytometry showed that untreated blasts with well-polar-
ized, red-emitting mitochondria localized in the upper
region of the plot (Figure 7A, left plot: high ΔΨm).
Blasts exposed to 40 μM a-bisabolol underwent a
progressive loss of red fluorescence, indicated by a shift
right and downward over 3 (Figure 7A, central plot:
intermediate ΔΨm) and 5 hours (Figure 7A, right plot:
low ΔΨm). In contrast, normal lymphocytes used as a
negative control did not suffer any changes in their
microscopy or cytofluorimetric pattern when exposed to
a similar a-bisabolol concentration, indicating that there
was no mitochondrial damage (Figure 7B, images and
plots), and that the cells remained vital. Finally, the
same blasts depicted in Figure 7A underwent PARP
cleavage and DNA laddering following a-bisabolol expo-
sure (Figure 7C).
Discussion
Forecasting the fraction of the lipophilic compound
a-bisabolol that was dissolved in water at given times
was a basic preliminary step to standardize the drug use
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in the conditions of our cytotoxicity tests. In these con-
ditions, we and an independent analytical laboratory
repeatedly measured that after 24 hours in culture med-
ium a-bisabolol lowered to around 65% of the theoreti-
cal concentrations added. In contrast, we could obtain
only a 2.5% solubility fraction in previous studies [1].
Thus, the present experiments led to define conditions
of maximal water solubility for a-bisabolol.
By cluster analysis, we separated out three subgroups
of leukemias with different sensitivities over 24 hours.
a-bisabolol was effective with an IC50 of 14 ± 5 μM in a
substantial proportion of Ph-B-ALL, and with an IC50 of
45 ± 7 μM in a substantial proportion of both Ph+B-
ALL and AML cases. Remarkably, these concentrations
spared normal circulating leukocytes and CD34+ and
CD33+my hematopoietic bone marrow precursors.
HUVECs, fibroblasts and hepatocytes were also spared
(personal observation). The third subgroup included
mainly, but not exclusively, AML samples with an IC50
value of 65 ± 5 μM. Thus, Ph-B-ALL cases were defi-
nitely more sensitive than AML cases, whose IC50 was
near to that observed in vitro also in normal leukocytes,
except lymphocytes, and in hematopoietic precursors.
Nevertheless, previous studies in animal models sug-
gested that similar a-bisabolol concentrations may be
safely administered through daily oral supplementation
even on a long-term basis [24,25]. The a-bisabolol con-
centrations that we found active against leukemic cells
in vitro are also lower than, or similar to, the concentra-
tions that we measured in the blood and in the brains
of healthy mice sacrificed after treatment with 1.4 g/Kg
a-bisabolol. In these mice the blood parameters of liver
and kidney fucntionality were preserved and, remark-
ably, the concentration in the brain exceeded 50 μM
without toxicity. Therefore, an active concentration of
a-bisabolol safely accumulated in a body environment
where lymphoid blasts have a tendency to localize and
survive protected from a number of curative drugs [26].
A dose of 10 mg/mouse a-bisabolol induced a decrease
in the number of palpable mammary tumor masses
without adverse reaction in HER-2 transgenic mice [2].
Ph+B-ALL cells were also sensitive to a-bisabolol. In
three cases (Ph+B-ALL #01, #04, #06 in Table 1) with
primary mutation of BCR/ABL, we observed a full effi-
cacy of a-bisabolol. In imatinib mesylate-sensitive blasts,
the association of a-bisabolol and imatinib mesylate led
to a synergistic effect which we have conclusively calcu-
lated as a CI<1 at any given Fa [16] in the BCR/ABL+
human cell line CML-T1. It is not clear, however,
whether the synergism depends on internalization
mechanics or on intracellular modulation of the dama-
ging actions of each or both drugs. A compound like
a-bisabolol - and others [27] - could help to identify
profitable new strategies for both mutated and non-
mutated leukemias [9,28,29].
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mitochondrial transmembrane potential (ΔΨm). (A) The
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Our biochemical data suggest a direct effect on mito-
chondrial integrity as a possible mechanism of a-bisabo-
lol damage to leukemic cells. This behavior is supported
by the observed oxygen consumption decrease in the
presence of glutamate/malate and by the unaffected
respiration rates in the presence of succinate/glycerol-3-
phosphate. Microscopy and flow cytometry data show
that a-bisabolol disrupts ΔΨm, which induces outer
membrane permeabilization and leads to the apoptotic
death of blasts. Our data not only implicate a-bisabolol
for the first time in mitochondrial impairment in human
leukemic cells but also suggest that this goes through a
peculiar model of cell death, i.e., the formation of a cel-
lular population with intermediate DΨ m which is a fea-
ture of apoptosis seen only in a few cell types and never
described to date in leukemic blasts [30].
In all leukemia samples treated with a-bisabolol, BID
was found to be expressed in a full-lenght form that was
suitable for binding to a-bisabolol. We failed to demon-
strate full-length BID translocation to the mitochondria
in leukemic cells as a pro-apoptotic mechanism [19].
Nevertheless, BID might act as a carrier that conveys a-
bisabolol to the mitochondrial membrane.
Thus, according to our previous and present work, a-
bisabolol enters cells via lipid rafts and directly involves
mitochondrial permeability transition pore opening [20],
which is responsible for the reduced glutamate/malate-
supported oxygen consumption and leads to disruption
of the mitochondrial membrane potential and pro-
grammed cell death. The reciprocal role of BID and a-
bisabolol [3] remains elusive in leukemic cells.
Conclusion
We provide here the first evidence that a-bisabolol is an
effective pro-apoptotic agent in primary ALL cells at
concentrations and durations that spare normal blood
and bone marrow cells. It retains cytotoxic potential in
both imatinib mesylate-resistant and -sensitive Ph+B-
ALL. It is also active against primary AML cells at
slightly higher concentrations. Our findings support a-
bisabolol as a possible candidate for the treatment of
acute leukemias and establish a basis for studies in
animal models.
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